» Articles » PMID: 11465306

Hip Fracture Prevention: Cost-effective Strategies

Overview
Specialty Pharmacology
Date 2001 Jul 24
PMID 11465306
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The available literature on cost benefit, cost effectiveness and cost utility of different drug and non-drug regimens in preventing hip fractures was reviewed. The cost of a hip fracture and of the different treatment regimens varied considerably from one country to another. In primary prevention, potential savings only exceeded costs in women over the age of 70 years treated with hormonal replacement therapy (HRT). In the case of HRT, treating those with low bone mineral density levels (secondary prevention) seems to be more cost effective than general treatment (primary prevention). There are few studies that have compared several different preventive regimens. Cost effectiveness is directly related to the cost of the regimen used because there is no significant difference in their effectiveness. That is, a high cost regimen such as bisphosphonates would be less cost effective than a low cost regimen such as HRT, judged from existing literature. High risk groups can be identified (nursing home residents) and treated with low cost interventions (calcium plus vitamin D or hip protectors). Considerable differences in the estimates used for the efficacy of different regimens in studies exist. Further studies comparing several hip fracture preventive regimens are required in order to establish the most cost-effective strategy.

Citing Articles

Efficacy of radiographic density values of the first and second cervical vertebrae recorded by CBCT technique to identify patients with osteoporosis and osteopenia.

Esmaeli F, Payahoo S, Mobasseri M, Johari M, Yazdani J J Dent Res Dent Clin Dent Prospects. 2017; 11(3):189-194.

PMID: 29184636 PMC: 5666220. DOI: 10.15171/joddd.2017.034.


Non-steroidal anti-inflammatory drugs and the risk of a second hip fracture: a propensity-score matching study.

Chuang P, Shen S, Yang T, Huang T, Huang K BMC Musculoskelet Disord. 2016; 17:201.

PMID: 27141945 PMC: 4855841. DOI: 10.1186/s12891-016-1047-2.


Fall mechanisms, bone strength, and hip fractures in elderly men and women in Taiwan.

Hwang H, Lee H, Huang H, Chen C, Lin M Osteoporos Int. 2010; 22(8):2385-93.

PMID: 20963399 DOI: 10.1007/s00198-010-1446-4.


Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006.

Abrahamsen B, Vestergaard P Osteoporos Int. 2009; 21(3):373-80.

PMID: 19436931 DOI: 10.1007/s00198-009-0957-3.


Non-pharmaceutical prevention of hip fractures - a cost-effectiveness analysis of a community-based elderly safety promotion program in Sweden.

Johansson P, Sadigh S, Tillgren P, Rehnberg C Cost Eff Resour Alloc. 2008; 6:11.

PMID: 18513425 PMC: 2440733. DOI: 10.1186/1478-7547-6-11.


References
1.
Cox M, Bowie R, Horne G . Hip fractures: an increasing health care cost. J Orthop Trauma. 1993; 7(1):52-7. View

2.
French F, Torgerson D, Porter R . Cost analysis of fracture of the neck of femur. Age Ageing. 1995; 24(3):185-9. DOI: 10.1093/ageing/24.3.185. View

3.
Visentin P, Ciravegna R, Fabris F . Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas. 1997; 26(3):185-92. DOI: 10.1016/s0378-5122(96)01099-7. View

4.
Grady D, Rubin S, Petitti D, Fox C, Black D, Ettinger B . Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117(12):1016-37. DOI: 10.7326/0003-4819-117-12-1016. View

5.
Gorsky R, Koplan J, Peterson H, Thacker S . Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol. 1994; 83(2):161-6. View